Skip Ribbon Commands
Skip to main content

​​​​​

​​

Primary Diagnosis

Coronary Artery Disease (CAD)

Stu​dy Purpose

The purpose of this study is to test the safety of taking aspirin plus 3 months of a second blood thinner (antiplatelet) medicine [such as clopidogrel (Plavix), or prasugrel (Effient), or ticagrelor (Brilinta)] in people who have a SYNERGY stent.​

Principal Investigator: Molly Szerlip, MD

Trial Details

Locations: Baylor Scott & White The Heart Hospital – Plano

Sponsor: Boston Scientific Corporation

IRB Number: 016-072

Trial Status: Enrolling

Exclusions: Adults only

Change in Care: Participating may change your care

Contact Information:

Heath Shirkey
469.814.4185
Heath.Shirkey@BSWHealth.org

Julie McCracken
469.814.4717
Julie.McCracken@BSWHealth.org​

Full Protocol Title

EVOLVE: A prospective, multicenter, single-arm study designed to assess the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk for bleeding undergoing percutaneous coronary intervention (PCI) with a SYNERGYTM Everolimus-Eluting Platinum Chromium Coronary Stent.

Get Detaile​d Information On Clinicaltrials.gov »​​​​​​​​​​​​​​​​​

​​

​​

​​​​​​​​​​BAYLOR SCOTT & WHITE RESEARCH ​INSTITUTE​​